Literature DB >> 21762961

An association study of thrombospondin 1 and 2 SNPs with coronary artery disease and myocardial infarction among South Indians.

Manickaraj Ashokkumar1, Chakrapani Anbarasan, Ramineni Saibabu, Sriram Kuram, Suresh C Raman, Koothurathu Mammen Cherian.   

Abstract

INTRODUCTION: Thrombospondin 1 and 2 are multidomain calcium-binding extracellular glycoproteins and they play a role in platelet aggregation, inflammatory response and assembly of connective tissue extracellular matrix. The association of thrombospondins (TSP) in the pathogenesis of coronary artery disease (CAD) and myocardial infarction (MI) is well established. The association of the TSP-1 (Asn700Ser, 2210A → G, rs2228262) and TSP-2 un-translated region (UTR) (3949T → G, rs8089) gene variations among South Indian CAD and MI patients has been examined in the present study.
MATERIALS AND METHODS: We analyzed the thrombospondin polymorphisms in unrelated CAD patients (n = 511) and a subgroup with an event of MI (n = 173) compared with controls (n = 522). The polymorphisms were assessed using polymerase chain reaction, restriction fragment length analysis and the circulating TSP concentration were measured using enzyme linked immune-sorbent assay.
RESULTS: The prevalence of TSP-1 and TSP-2 alleles did not show any significant difference statistically, when compared controls against CAD/MI patients. The rare GG genotype of the N700S polymorphism was not observed among the studied population. Further, multiple regression analysis revealed that there was no significant risk for CAD (OR = 1.68; 95% CI 0.927 - 3.055; p = 0.087) or MI (OR = 1.84; 95% CI 0.846 - 4.007; p = 0.124) for the GA genotype. The GA genotype showed no impact on clinical characteristics of the CAD patients and their circulating TSP-1 levels. A similar non-association was observed for the TSP-2 in 3949T → G polymorphism (GG genotype) for CAD (OR = 0.64; 95% CI 0.278 - 1.455; p = 0.636) and MI (OR = 0.53; 95% CI 0.166 - 1.675; p = 0.278).
CONCLUSIONS: Our data suggests that the presence of thrombospondin-1 (rs2228262) and thrombospondin-2 (rs8089) variants need not be considered a risk for coronary artery disease or myocardial infarction among South Indians.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762961     DOI: 10.1016/j.thromres.2011.05.026

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

Review 1.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

2.  Progression of lumbar spinal stenosis is influenced by polymorphism of thrombospondin 2 gene in the Korean population.

Authors:  Seung-Jae Hyun; Borae G Park; Seung-Chul Rhim; Jun-Won Jang; Sang-Ryong Jeon; Sung-Woo Roh
Journal:  Eur Spine J       Date:  2013-06-27       Impact factor: 3.134

3.  Association of THBS1 rs1478605 T>C in 5'-untranslated regions with the development and progression of gastric cancer.

Authors:  Bin-Bin Hong; Shu-Qin Chen; Yuan-Lin Qi; Jin-Wei Zhu; Jian-Yin Lin
Journal:  Biomed Rep       Date:  2015-01-05

Review 4.  Thrombospondins: old players, new games.

Authors:  Olga Stenina-Adognravi
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

Review 5.  Thrombospondins: A Role in Cardiovascular Disease.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2017-07-17       Impact factor: 5.923

6.  Identification of Missense Extracellular Matrix Gene Variants in a Large Glaucoma Pedigree and Investigation of the N700S Thrombospondin-1 Variant in Normal and Glaucomatous Trabecular Meshwork Cells.

Authors:  Mary K Wirtz; Renee Sykes; John Samples; Beth Edmunds; Dongseok Choi; Douglas R Keene; Sara F Tufa; Ying Ying Sun; Kate E Keller
Journal:  Curr Eye Res       Date:  2021-07-06       Impact factor: 2.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.